Lange Carsten, Bednarski Patrick J
University of Greifswald - Institute of Pharmacy, Greifswald, Germany.
Curr Pharm Des. 2016;22(46):6956-6974. doi: 10.2174/1381612822666161124155344.
The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
将光敏剂、光和双氧用于疾病治疗已被称为光动力疗法(PDT),该疗法于一百多年前首次被发现。多年来,在众多临床研究中,除了传统癌症治疗外,光动力疗法已证明其在治疗恶性和非恶性病变方面的潜力,但作为一种常规方法的应用仍然有限。在这篇综述中,简要描述了自二十世纪初以来现代光动力疗法的发展。解释了光毒性的潜在机制,并强调了对理想光敏剂(PS)的要求。介绍了选定的光敏剂,并回顾了通过开发具有改进化学和光毒性特性的新型光敏剂来优化光动力疗法的众多尝试中的一些例子。介绍了有前景的第三代光敏剂,并讨论了提高光动力疗法肿瘤选择性和疗效的新方法,例如使用纳米颗粒。